New Clinical Trial: Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors (NCT02574728)
WHY IT MATTERS
This trial offers a potential new treatment option for children with recurrent or refractory cancers who have limited alternatives, though enrollment is currently closed.
Researchers at Emory University are testing a new combination of medicines for children whose cancer has come back or stopped responding to previous treatments. The study combines three drugs: sirolimus (which slows cell growth), celecoxib (an anti-inflammatory), and two chemotherapy drugs given in low doses. The goal is to see if this combination works better than standard treatments for solid tumors and brain cancers in children.
NCT ID: NCT02574728 Status: ACTIVE_NOT_RECRUITING Conditions: Cancer Phase: PHASE2 Enrollment: 46 Sponsor: Emory University Summary: This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
ASK YOUR DOCTOR
If your child has relapsed or refractory cancer, ask your oncologist whether this trial might be relevant or if similar combination approaches are being used at your treatment center.